Long progression-free survival with first-line paclitaxel plus platinum is associated with improved response and progression-free survival with second-line docetaxel in advanced non-small-cell lung cancer

被引：0
|
作者：
Eleazar Omar Macedo-Pérez
Vicente Morales-Oyarvide
Víctor Osvaldo Mendoza-García
Yuzmiren Dorantes-Gallareta
Diana Flores-Estrada
Oscar Arrieta
机构：
[1] Instituto Nacional de Cancerología (INCan),Clinic of Thoracic Oncology
[2] Instituto Nacional de Cancerología (INCan),Experimental Oncology Laboratory
来源：
Cancer Chemotherapy and Pharmacology | 2014年 / 74卷
关键词：
Docetaxel; Paclitaxel; Lung cancer; Second-line;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：681 / 690
页数：9
相关论文
共 50 条
  • [1] Long progression-free survival with first-line paclitaxel plus platinum is associated with improved response and progression-free survival with second-line docetaxel in advanced non-small-cell lung cancer
    Omar Macedo-Perez, Eleazar
    Morales-Oyarvide, Vicente
    Osvaldo Mendoza-Garcia, Victor
    Dorantes-Gallareta, Yuzmiren
    Flores-Estrada, Diana
    Arrieta, Oscar
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (04) : 681 - 690
  • [2] LONG PROGRESSIVE FREE SURVIVAL TO PACLITAXEL AND CISPLATIN IN FIRST LINE IS ASSOCIATED WITH BETTER RESPONSE AND PROGRESSION FREE SURVIVAL TO DOCETAXEL IN SECOND LINE IN ADVANCED NON-SMALL CELL LUNG CANCER
    Macedo, Eleazar O.
    Arrieta, Oscar
    Orta, David
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1182 - S1182
  • [3] Lenvatinib as first-line treatment for advanced thyroid cancer: long progression-free survival
    Simone De Leo
    Marta Di Stefano
    Luca Persani
    Laura Fugazzola
    Carla Colombo
    Endocrine, 2021, 72 : 462 - 469
  • [4] Lenvatinib as first-line treatment for advanced thyroid cancer: long progression-free survival
    De Leo, Simone
    Di Stefano, Marta
    Persani, Luca
    Fugazzola, Laura
    Colombo, Carla
    ENDOCRINE, 2021, 72 (02) : 462 - 469
  • [5] Progression-free survival in first-line chemotherapy is a prognostic factor in second-line chemotherapy in patients with advanced gastric cancer
    Kenji Hashimoto
    Atsuo Takashima
    Kengo Nagashima
    Shun-suke Okazaki
    Takako Eguchi Nakajima
    Ken Kato
    Tetsuya Hamaguchi
    Yasuhide Yamada
    Yasuhiro Shimada
    Journal of Cancer Research and Clinical Oncology, 2010, 136 : 1059 - 1064
  • [6] Time trends in overall survival (OS) and progression-free survival (PFS) in the first-line treatment of advanced non-small-cell lung cancer (NSCLC).
    Rutkowski, Jacek
    Saad, Everardo D.
    Buyse, Marc E.
    Jassem, Jacek
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [7] Progression-free survival in first-line chemotherapy is a prognostic factor in second-line chemotherapy in patients with advanced gastric cancer
    Hashimoto, Kenji
    Takashima, Atsuo
    Nagashima, Kengo
    Okazaki, Shun-suke
    Nakajima, Takako Eguchi
    Kato, Ken
    Hamaguchi, Tetsuya
    Yamada, Yasuhide
    Shimada, Yasuhiro
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2010, 136 (07) : 1059 - 1064
  • [8] First-Line Maintenance With Erlotinib/Bevacizumab Improves Progression-Free Survival in Advanced Lung Cancer
    不详
    ONCOLOGY-NEW YORK, 2009, 23 (02): : 182 - +
  • [9] Progression-free survival as a surrogate for overall survival in first-line chemotherapy for advanced pancreatic cancer
    Hamada, Tsuyoshi
    Nakai, Yousuke
    Isayama, Hiroyuki
    Yasunaga, Hideo
    Matsui, Hiroki
    Takahara, Naminatsu
    Mizuno, Suguru
    Kogure, Hirofumi
    Matsubara, Saburo
    Yamamoto, Natsuyo
    Tada, Minoru
    Koike, Kazuhiko
    EUROPEAN JOURNAL OF CANCER, 2016, 65 : 11 - 20
  • [10] Progression-free survival and post-progression survival in patients with advanced gastric cancer treated with first-line chemotherapy
    Shitara, Kohei
    Matsuo, Keitaro
    Muro, Kei
    Doi, Toshihiko
    Ohtsu, Atsushi
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2013, 139 (08) : 1383 - 1389
12345